David M. Brown, MD

Associate Professor of Clinical Ophthalmology, Academic Institute
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


After completing his postdoctoral training, Dr. Brown joined the faculty at the Baylor College of Medicine as a Clinical Instructor in the Department of Ophthalmology. He received his faculty appointment at the Weill Medical College in 2006.

Description of Research

Dr. Brown’s research centers on clinical investigations to evaluate treatments for diabetic retinopathy, neovascular age-related macular degeneration, central retinal vein occlusion, and retinal detachment. Dr. Brown was a key investigator on the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-related Macular Degeneration (ANCHOR) Study and the Minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular AMD (MARINA) Study which both demonstrated a statistically significant benefit of Lucentis (ranibizumab) over Visudyne (verteporfin photodynamic therapy [PDT]) in predominantly classic choroidal neovascularization (CNV). Dr. Brown is also a member of the Diabetic Retinopathy Clinical Research Network.

Areas Of Expertise

Diabetic retinopathy Neovascular age-related macular degeneration Central retinal vein occlusion Retinal detachment
Education & Training

MD, Baylor College of Medicine
Internship, Baylor College of Medicine
Clinical Fellowship
Residency, University of Iowa Hospitals and Clinics

Major, JC, Lampen, SIR, Wykoff, CC, Ou, WC, Brown, DM, Wong, TP & Shah, AR 2020, Retina (Philadelphia, Pa.), vol. 40, no. 3, pp. 552-556. https://doi.org/10.1097/IAE.0000000000002431

Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up
Zhou, B, Mitchell, TC, Rusakevich, AM, Brown, DM & Wykoff, CC 2020, American Journal of Ophthalmology, vol. 210, pp. 86-96. https://doi.org/10.1016/j.ajo.2019.10.012

HAWK and HARRIER Study Investigators 2019, Ophthalmology, vol. 126, no. 12, pp. e96-e97. https://doi.org/10.1016/j.ophtha.2019.08.016

Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in Patients with Diabetic Macular Edema
Fang, M, Fan, W, Shi, Y, Ip, MS, Wykoff, CC, Wang, K, Falavarjani, KG, Brown, DM, van Hemert, J & Sadda, SVR 2019, American Journal of Ophthalmology, vol. 206, pp. 74-81. https://doi.org/10.1016/j.ajo.2019.03.030

Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on Ultrawide-Field Fluorescein Angiography
Fan, W, Nittala, MG, Fleming, A, Robertson, G, Uji, A, Wykoff, CC, Brown, DM, van Hemert, J, Ip, M, Wang, K, Falavarjani, KG, Singer, M, Sagong, M & Sadda, SVR 2019, American Journal of Ophthalmology. https://doi.org/10.1016/j.ajo.2019.08.015

Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies
Feltgen, N, Ogura, Y, Boscia, F, Holz, FG, Korobelnik, JF, Brown, DM, Heier, JS, Stemper, B, Rittenhouse, KD, Asmus, F, Ahlers, C, Vitti, R, Saroj, N & Mitchell, P 2019, Ophthalmology Retina, vol. 3, no. 7, pp. 553-560. https://doi.org/10.1016/j.oret.2019.02.010

Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes
TREX-DME Study Group 2019, American Journal of Ophthalmology, vol. 202, pp. 91-99. https://doi.org/10.1016/j.ajo.2019.02.005

Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4
Domalpally, A, Clemons, TE, Bressler, SB, Danis, RP, Elman, M, Kim, JE, Brown, DM & Chew, EY 2019, Ophthalmology Retina, vol. 3, no. 4, pp. 326-335. https://doi.org/10.1016/j.oret.2019.01.004

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
HAWK and HARRIER Study Investigators 2019, Ophthalmology. https://doi.org/10.1016/j.ophtha.2019.04.017

Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index
Ehlers, JP, Uchida, A, Hu, M, Figueiredo, N, Kaiser, PK, Heier, JS, Brown, DM, Boyer, DS, Do, DV, Gibson, A, Saroj, N & Srivastava, SK 2019, Ophthalmology Retina. https://doi.org/10.1016/j.oret.2019.06.010

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial
Liao, DS, Grossi, FV, El Mehdi, D, Gerber, MR, Brown, DM, Heier, JS, Wykoff, CC, Singerman, LJ, Abraham, P, Grassmann, F, Nuernberg, P, Weber, BHF, Deschatelets, P, Kim, RY, Chung, CY, Ribeiro, RM, Hamdani, M, Rosenfeld, PJ, Boyer, DS, Slakter, JS & Francois, CG 2019, Ophthalmology. https://doi.org/10.1016/j.ophtha.2019.07.011

Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial
RECOVERY Study Group 2019, Ophthalmology Retina. https://doi.org/10.1016/j.oret.2019.07.011

Intravitreal Combined Aflibercept + Anti–Platelet-Derived Growth Factor Receptor ß for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial
Heier, JS, Wykoff, CC, Waheed, NK, Kitchens, JW, Patel, SS, Vitti, R, Perlee, L, Chu, KW, Leal, S, Asmus, F, Son, V, Schmelter, T & Brown, DM 2019, Ophthalmology. https://doi.org/10.1016/j.ophtha.2019.09.021

Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16
AREDS2 Research Group 2018, Ophthalmology, vol. 125, no. 12, pp. 1913-1928. https://doi.org/10.1016/j.ophtha.2018.05.028

Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies
Mitchell, P, McAllister, I, Larsen, M, Staurenghi, G, Korobelnik, JF, Boyer, DS, Do, DV, Brown, DM, Katz, TA, Berliner, A, Vitti, R, Zeitz, O, Metzig, C, Lu, C & Holz, FG 2018, Ophthalmology Retina, vol. 2, no. 10, pp. 988-996. https://doi.org/10.1016/j.oret.2018.02.011

Suprachoroidal space alterations following delivery of triamcinolone acetonide: Post-hoc analysis of the phase 1/2 HULK study of patients with diabetic macular edema
Lampen, SIR, Khurana, RN, Noronha, G, Brown, DM & Wykoff, CC 2018, Ophthalmic Surgery Lasers and Imaging Retina, vol. 49, no. 9, pp. 692-697. https://doi.org/10.3928/23258160-20180831-07

Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study
Kwon, S, Wykoff, CC, Brown, DM, van Hemert, J, Fan, W & Sadda, SR 2018, British Journal of Ophthalmology, vol. 102, no. 8, pp. 1066-1071. https://doi.org/10.1136/bjophthalmol-2017-311475

Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial
TREX-AMD Study Group 2018, American Journal of Ophthalmology, vol. 192, pp. 84-90. https://doi.org/10.1016/j.ajo.2018.05.008

Suprachoroidal Triamcinolone Acetonide for Diabetic Macular Edema: The HULK Trial
HULK Study Group 2018, Ophthalmology Retina, vol. 2, no. 8, pp. 874-877. https://doi.org/10.1016/j.oret.2018.03.008

Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema
Payne, JF, Clark, WL, Bruce, BB, Wykoff, CC, Brown, DM, Menke, BM, Iverson, SM, Allen, KF, Boyer, DS & Treat & Extend Protocol in Patients with Diabetic Macular Edema Study Group 2018, Ophthalmology. https://doi.org/10.1016/j.ophtha.2018.03.046

Live Chat Available